Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Children's Hospital & Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Basic Clin Pharmacol Toxicol. 2020 Feb;126(2):133-143. doi: 10.1111/bcpt.13315. Epub 2019 Sep 4.
Metronidazole, a widely used drug for the treatment of infections with anaerobic and facultative anaerobic bacteria and protozoa, can frequently cause metronidazole-induced cutaneous adverse reactions (McADRs). The aim of the present study was to investigate the association between human leucocyte antigen (HLA) alleles and McADRs in a Chinese Han population. The frequency of HLA-B24:02 carriers among the McADR patients was 73.3%, which was significantly higher than that of the population controls (32.16%, OR = 5.80, 95% CI = [1.80-18.72], Pc = 0.004) and of the metronidazole-tolerant patients (26.67%, OR = 7.56, 95% CI = [2.02-28.35], Pc = 0.004). Molecular docking showed that metronidazole and one of its major metabolites had the potential to bind in the HLA groove and that there was a relatively stable binding state of the HLA-B24:02-metronidazole/the metabolite complex. The CDR3 repertoires of both T cell receptor (TCR)Vα and Vβ of the patients showed a significantly skewed or an oligoclonal distribution. The TCRVβ CDR3 of the patients shared a similar motif, "CASSxxxxxxQxF." The current study demonstrated that both the HLA-A*24:02 allele and TCR are involved in the pathogenesis of McADRs.
甲硝唑是一种广泛用于治疗需氧菌和兼性厌氧菌及原生动物感染的药物,常可引起甲硝唑诱导的皮肤不良反应(McADRs)。本研究旨在探讨人类白细胞抗原(HLA)等位基因与中国汉族人群中 McADRs 的关系。McADR 患者中 HLA-B24:02 携带者的频率为 73.3%,明显高于人群对照(32.16%,OR=5.80,95%CI=[1.80-18.72],Pc=0.004)和甲硝唑耐受患者(26.67%,OR=7.56,95%CI=[2.02-28.35],Pc=0.004)。分子对接显示,甲硝唑及其一种主要代谢物有可能结合到 HLA 凹槽中,并且 HLA-B24:02-甲硝唑/代谢物复合物具有相对稳定的结合状态。患者的 T 细胞受体(TCR)Vα和 Vβ的 CDR3 谱均表现出明显的偏斜或寡克隆分布。患者的 TCRVβ CDR3 共享一个相似的基序,“CASSxxxxxxQxF”。本研究表明,HLA-A*24:02 等位基因和 TCR 均参与 McADRs 的发病机制。
Basic Clin Pharmacol Toxicol. 2018-4-25
Pharmacogenomics J. 2020-6
Basic Clin Pharmacol Toxicol. 2011-3-16
Clin Transl Sci. 2021-9
Front Pharmacol. 2021-4-26